GOVX-B11 HIV Vaccine Description
GOVX-B11 is a Clade B HIV vaccine candidate targeted for use in the Americas, Europe, Japan, and Australia.
GOVX-B11 is a vaccine candidate that uses recombinant DNA and recombinant modified vaccinia Ankara (MVA) vaccines to express non-infectious virus-like particles.
The GOVX-B11 vaccine consists of a recombinant DNA vaccine used to prime immune responses and a recombinant MVA vaccine used to boost the primed responses.
GOVX-B11 HIV Vaccine Indication
GOVX-B11 is indicated to prevent HIV disease
GOVX-B11 HIV Vaccine Dosage
The proposed regimen for the Phase 2b efficacy trial consists of DNA delivered into the muscle with a needle and syringe at 0 and 2 months and MVA delivered into the muscle with a needle and syringe at 4, 6 and 10 months (DDMM_M regimen).
GOVX-B11 HIV Vaccine Clinical Trials